ClinicalTrials.gg
CompletedNCT04524390EMBARKUpdated Mar 19, 2025Results posted

Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai

A Phase 2 interventional study of Maralixibat and Placebo in Biliary Atresia, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 22 sites in 8 countries. Open to participants aged 21 Days to 111 Days. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
21 Days to 111 Days
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Biliary Atresia with a site in United States — 8 open to participants now, 10 under way, 2 of them phase 3. Biliary Atresia · United States.

Enrollment
7th of 14
75 · median 53
Started
2021
the only one that year
Phase 2
4 of 22
1 open now
Registered
17th of 22
by date
Lead sponsor
2 of 22
Mirum Pharmaceuticals, Inc.

Among the 22 studies in Biliary Atresia with a site in United States, this one is the 7th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2021, is one of 4 in phase 2, and was the 17th registered.

Biliary Atresia

77 studies on the registry are indexed under Biliary Atresia; 25 are open to participants now.

Browse Biliary Atresia studies →

Open to participants now

8 of the 22 studies in Biliary Atresia with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 21 Biliary Atresia studies recruiting now, 3 (14%) set no upper age limit and 18 (86%) stop at 75 or younger; 21 take children under 18; 6 take healthy volunteers.

This study: 21 Days to 111 Days · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Biliary Atresia with a site in United States, or all of them as a file.
02

Study summary

A study to evaluate the efficacy and safety of maralixibat in infants with Biliary Atresia (BA) after Hepatoportoenterostomy (HPE, also known as the Kasai procedure).

Read the detailed description

This is a double-blind randomized, placebo-controlled study in subjects with Biliary Atresia with a primary endpoint at Week 26 followed by long-term open-label period during which all subjects will receive maralixibat to Week 104.

03

Conditions studied

  • Biliary Atresia

Keywords

  • Biliary Atresia
  • Kasai
  • Biliary Tract Diseases
  • Bile Duct Diseases
  • Congenital Abnormalities
04

Who can participate

Ages eligible
21 Days to 111 Days
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects with body weight ≥2500 g, who are ≥21 days old and \<90 days old at the time of HPE (Kasai)
  2. HPE or Kasai Procedure within 3 weeks prior to randomization
  3. Clinical diagnosis of biliary atresia

Exclusion criteria

Exclusion Criteria:

  1. Subjects with intractable chronic diarrhea at randomization
  2. Subjects not tolerating enteral feeds at randomization
  3. History of ileal resection
  4. Diagnosis of biliary atresia splenic malformation syndrome or cystic biliary atresia
  5. Evidence of another non-biliary atresia pathology involving the intrahepatic bile duct (e.g., paucity, sclerosing cholangitis)
  6. Evidence of liver failure (e.g. significant ascites)
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Double Blind - Maralixibat

    The double-blind period comprised of 4-8 weeks of dose escalation followed by 18 - 22 weeks of stable dosing treatment, after which participants were transferred to the open-label arm.

    Drug: Maralixibat

  • Placebo comparator
    Double Blind - Placebo

    The double-blind period comprised of 4-8 weeks of dose escalation followed by 18 - 22 weeks of stable dosing treatment, after which participants were transferred to the open-label arm.

    Other: Placebo

  • Experimental
    Open Label - Maralixibat

    The Open-Label period comprised of 4-8 weeks of dose escalation followed by 70 - 74 weeks of stable dosing treatment. During the OLE, all participants, regardless of treatment assignment in the double-blind period, received maralixibat.

    Drug: Maralixibat

Interventions

  • A small molecule inhibitor of the ileal bile acid transporter (IBAT)

    Also known as: Formerly LUM001 and SHP625

  • OtherPlacebo

    Identical to maralixibat except for the active drug substance

06

What researchers measure

Primary outcomes

  1. Mean Change in Total Serum Bilirubin Levels

    Time frame: From baseline to Week 26

Secondary outcomes

  1. Mean Change in Total Serum Bile Acids

    Time frame: From baseline to Week 26

  2. Proportion of Participants With Mean TSB Levels <2 mg/dL Through Week 26

    Time frame: From baseline to Week 26

  3. Proportion of Participants Observed to Have a Liver-related Clinical Event Transplantation, Liver Decompensation, Discontinuations Due to Liver Related Events, or Death.

    Liver decompensation (hepatic encephalopathy, variceal bleeding, new persistent ascites)

    Time frame: From Baseline to Week 26

  4. Proportion of Participants Undergoing Liver Transplantation or Death

    Time frame: From Baseline to Week 26

  5. Proportion of Participants Observed to Develop Clinically Evident Portal Hypertension Defined as Splenomegaly and Thrombocytopenia (Platelet Count <150 x 109/L) or Clinically Evident Ascites or Endoscopic Evidence of Esophageal or Gastric Varices.

    Splenomegaly =\> (spleen size \>2 cm below the costal margin palpated on physical examination)

    Time frame: From Baseline to Week 26

  6. Proportion of Participants With Mean TSB Levels ≤1.2 mg/dL

    Time frame: From Baseline to Week 26

  7. Proportion of Participants With Mean sBA Levels ≤40 mmol/L

    Time frame: From Baseline to Week 26

07

Results

Posted Feb 17, 2025

Participant flow

A total of 75 participants were enrolled at 19 sites across 8 countries (China, Germany, Poland, Singapore, Taiwan, United Kingdom, United States, and Vietnam).

Double Blind
Participant flow — Double Blind
MilestoneDouble Blind - MaralixibatDouble Blind - PlaceboOpen Label - Maralixibat
Started40350
Completed28240
Not completed12110
Withdrew: Consent withdrawal by subject210
Withdrew: Adverse event530
Withdrew: Liver transplant560
Withdrew: Disease progression010
Open-Label
Participant flow — Open-Label
MilestoneDouble Blind - MaralixibatDouble Blind - PlaceboOpen Label - Maralixibat
Started0052
Completed001
Not completed0051
Withdrew: Drug interruption criteria001
Withdrew: Liver transplant001
Withdrew: Disease progression001
Withdrew: Adverse event003
Withdrew: Study termination by sponsor0045

Outcome measures

PrimaryMean Change in Total Serum Bilirubin Levels
Time frame:
From baseline to Week 26
Reported as:
Least squares mean · mg/dl
Mean Change in Total Serum Bilirubin Levels
mg/dlDouble Blind - MaralixibatDouble Blind - Placebo
Mean Change in Total Serum Bilirubin Levels-3.5 ± 0.853-3.11 ± 0.947
Statistical analysis
  • Double Blind - Maralixibat vs Double Blind - Placebo · MMRM · p = 0.7419 · Least-square mean: -0.39 · 95% CI -2.76 to 1.97
SecondaryMean Change in Total Serum Bile Acids
Time frame:
From baseline to Week 26
Reported as:
Least squares mean · umol/L
Mean Change in Total Serum Bile Acids
umol/LDouble Blind - MaralixibatDouble Blind - Placebo
Mean Change in Total Serum Bile Acids-51.19 ± 24.436-5.29 ± 28.440
Statistical analysis
  • Double Blind - Maralixibat vs Double Blind - Placebo · MMRM · p = 0.2002 · Least-square mean: -45.9 · 95% CI -116.86 to 25.05
SecondaryProportion of Participants With Mean TSB Levels <2 mg/dL Through Week 26
Time frame:
From baseline to Week 26
Reported as:
Count of participants · Participants
Proportion of Participants With Mean TSB Levels <2 mg/dL Through Week 26
ParticipantsDouble Blind - MaralixibatDouble Blind - Placebo
Proportion of Participants With Mean TSB Levels <2 mg/dL Through Week 262420
Statistical analysis
  • Double Blind - Maralixibat vs Double Blind - Placebo · Barnard's exact test · p = 0.8412
SecondaryProportion of Participants Observed to Have a Liver-related Clinical Event Transplantation, Liver Decompensation, Discontinuations Due to Liver Related Events, or Death.

Liver decompensation (hepatic encephalopathy, variceal bleeding, new persistent ascites)

Time frame:
From Baseline to Week 26
Reported as:
Count of participants · Participants
Proportion of Participants Observed to Have a Liver-related Clinical Event Transplantation, Liver Decompensation, Discontinuations Due to Liver Related Events, or Death.
ParticipantsDouble Blind - MaralixibatDouble Blind - Placebo
Proportion of Participants Observed to Have a Liver-related Clinical Event Transplantation, Liver Decompensation, Discontinuations Due to Liver Related Events, or Death.87
Statistical analysis
  • Double Blind - Maralixibat vs Double Blind - Placebo · Barnard's exact test · p = > 0.9999
SecondaryProportion of Participants Undergoing Liver Transplantation or Death
Time frame:
From Baseline to Week 26
Reported as:
Count of participants · Participants
Proportion of Participants Undergoing Liver Transplantation or Death
ParticipantsDouble Blind - MaralixibatDouble Blind - Placebo
Proportion of Participants Undergoing Liver Transplantation or Death53
Statistical analysis
  • Double Blind - Maralixibat vs Double Blind - Placebo · Barnard's exact test · p = 0.6658
SecondaryProportion of Participants Observed to Develop Clinically Evident Portal Hypertension Defined as Splenomegaly and Thrombocytopenia (Platelet Count <150 x 109/L) or Clinically Evident Ascites or Endoscopic Evidence of Esophageal or Gastric Varices.

Splenomegaly =\> (spleen size \>2 cm below the costal margin palpated on physical examination)

Time frame:
From Baseline to Week 26
Reported as:
Count of participants · Participants
Proportion of Participants Observed to Develop Clinically Evident Portal Hypertension Defined as Splenomegaly and Thrombocytopenia (Platelet Count <150 x 109/L) or Clinically Evident Ascites or Endoscopic Evidence of Esophageal or Gastric Varices.
ParticipantsDouble Blind - MaralixibatDouble Blind - Placebo
Proportion of Participants Observed to Develop Clinically Evident Portal Hypertension Defined as Splenomegaly and Thrombocytopenia (Platelet Count <150 x 109/L) or Clinically Evident Ascites or Endoscopic Evidence of Esophageal or Gastric Varices.34
Statistical analysis
  • Double Blind - Maralixibat vs Double Blind - Placebo · Barnard's exact test · p = 0.6236
SecondaryProportion of Participants With Mean TSB Levels ≤1.2 mg/dL
Time frame:
From Baseline to Week 26
Reported as:
Count of participants · Participants
Proportion of Participants With Mean TSB Levels ≤1.2 mg/dL
ParticipantsDouble Blind - MaralixibatDouble Blind - Placebo
Proportion of Participants With Mean TSB Levels ≤1.2 mg/dL2318
Statistical analysis
  • Double Blind - Maralixibat vs Double Blind - Placebo · Barnard's exact test · p = 0.6658
SecondaryProportion of Participants With Mean sBA Levels ≤40 mmol/L
Time frame:
From Baseline to Week 26
Reported as:
Count of participants · Participants
Proportion of Participants With Mean sBA Levels ≤40 mmol/L
ParticipantsDouble Blind - MaralixibatDouble Blind - Placebo
Proportion of Participants With Mean sBA Levels ≤40 mmol/L107
Statistical analysis
  • Double Blind - Maralixibat vs Double Blind - Placebo · Barnard's exact test · p = 0.6659

Adverse events

Collected over Baseline to EOT. In this study the longest time frame was 102.4 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double Blind - Maralixibat0/40 (0%)26/40 (65%)38/40 (95%)
Double Blind - Placebo0/35 (0%)25/35 (71.4%)33/35 (94.3%)
Open Label - Maralixibat0/52 (0%)21/52 (40.4%)47/52 (90.4%)
Most frequent serious events
Showing 10 of 42
Most frequent serious events
EventDouble Blind - MaralixibatDouble Blind - PlaceboOpen Label - Maralixibat
CholangitisHepatobiliary disorders15/4017/358/52
PneumoniaInfections and infestations8/404/352/52
COVID-19Infections and infestations1/403/350/52
SepsisInfections and infestations0/402/350/52
Hepatic enzyme increasedInvestigations2/400/351/52
DiarrhoeaGastrointestinal disorders2/400/350/52
BronchiolitisInfections and infestations2/401/351/52
Parainfluenzae virus infectionInfections and infestations2/400/350/52
Adenovirus infectionInfections and infestations0/400/352/52
GastroenteritisInfections and infestations0/400/352/52
Most frequent other events
Showing 10 of 39
Most frequent other events
EventDouble Blind - MaralixibatDouble Blind - PlaceboOpen Label - Maralixibat
PyrexiaGeneral disorders14/408/3512/52
DiarrhoeaGastrointestinal disorders13/408/3513/52
Vitamin D deficiencyMetabolism and nutrition disorders7/409/358/52
Upper respiratory tract infectionInfections and infestations7/403/3512/52
CoughRespiratory, thoracic and mediastinal disorders8/405/358/52
Vitamin A deficiencyMetabolism and nutrition disorders3/407/353/52
VomitingGastrointestinal disorders4/406/352/52
CholangitisHepatobiliary disorders6/406/353/52
EczemaSkin and subcutaneous tissue disorders6/404/351/52
PneumoniaInfections and infestations6/405/355/52

Baseline characteristics

Age, Customized
Age, Customized(participants)Double Blind Period - PlaceboDouble Blind - MaralixibatTotal
Infants and toddlers (28 days-23 months)354075
Sex: Female, Male
Sex: Female, Male(Participants)Double Blind Period - PlaceboDouble Blind - MaralixibatTotal
Female152136
Male201939
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double Blind Period - PlaceboDouble Blind - MaralixibatTotal
Race — Asian283159
Race — White5813
Race — More than one race011
Race — Not Reported101
Race — Other101
Region of Enrollment
Region of Enrollment(Participants)Double Blind Period - PlaceboDouble Blind - MaralixibatTotal
Vietnam8917
Singapore011
United States145
China181836
Taiwan123
Poland112
United Kingdom6410
Germany011
08

Study locations

22 sites
  • Phoenix Children's Division of Gastroenterology & Hepatology
    Phoenix, Arizona 85016, United States
  • Children's Healthcare of Atlanta - Emory University School of Medicine
    Atlanta, Georgia 30329, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • NYU Grossman School of Medicine
    New York, New York 10016, United States
  • New York-Presbyterian - Columbia University Medical Center
    New York, New York 10032, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Beijing Pediatric Research Institute
    Beijing, Beijing 100020, China
  • Guangzhou Women and Children's Medical Center
    Guangzhou, Guangdong 510623, China
  • The Children's Hospital, Zhejiang University School of Medicine
    Hanzhou, Zhejiang 310058, China
  • Children's hospital of Shanghai
    Shanghai, 200062, China
  • Children's Hospital of Fudan University
    Shanghai, 201102, China
  • Hannover Medical School
    Hanover, Germany
  • Instytut Pomnik-Centrum Zdrowia Dziecka
    Warsaw, Poland
  • KK women's and Children's hospital
    Bukit Timah, 229899, Singapore
  • Taichung Veterans General Hospital
    Taichung, 407, Taiwan
  • Linkou Chang Gung Memorial Hospital
    Taoyuan, 333, Taiwan
  • Birmingham Children's Hospital
    Birmingham, B4 6NH, United Kingdom
  • King's College Hospital NHS
    London, United Kingdom
  • Hue Central Hospital
    Huế, Thừa Thiên Huế, Vietnam
  • Vietnam National Children's Hospital
    Hanoi, 115000, Vietnam
  • Children's Hospital No. 1
    Ho Chi Minh City, 740500, Vietnam
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Nov 2023, 27 months.

Results were first posted in Feb 2025, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2020
First posted
Aug 24, 2020
StartActual
Jul 8, 2021
Primary completionActual
Nov 7, 2023
CompletionActual
Feb 7, 2024
Results first posted
Feb 17, 2025
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04524390
Responsible party
Sponsor
First posted
Aug 24, 2020
Start date
Jul 8, 2021
Primary completion
Nov 7, 2023
Completion
Feb 7, 2024
Results posted
Feb 17, 2025
Last update
Mar 19, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Maralixibat

Start the discussion